Phase 4
Completed N=44
Resveratrol for Pain Due to Endometriosis
Source: ClinicalTrials.gov NCT02475564 ↗Enrolled (actual)
44
Serious AEs
0.0%
Results posted
Aug 2016
Primary outcomePrimary: Pain Scores Measured by VAS (Visual Analog Scale) at Day 42. — 3.2; 3.9 units on a scale — p=0.7
◆ Published Evidence
Highly cited
540citations · ~42 / year
Consensus on current management of endometriosis.
Summary
This study aims to verify whether the use of 40 mg of resveratrol per day associated with monophasic contraceptive pill (levonorgestrel 0.15mg/ethinyl estradiol 0.03mg) reduces pelvic pain at the end of 2 months of treatment, compared to the use of the pill with placebo.
Linked Publications (3)
-
Consensus on current management of endometriosis.
-
Advantages of the association of resveratrol with oral contraceptives for management of endometriosis-related pain.
-
Resveratrol and endometrium: a closer look at an active ingredient of red wine using in vivo and in vitro models.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain Scores Measured by VAS (Visual Analog Scale) at Day 42. |
3.2; 3.9 | 0.7 |
| SECONDARY Serum CA125 Levels at 42 Days |
11.7; 13.7 | 0.1 |
| SECONDARY Serum Prolactin Levels at 42 Days |
12; 11.1 | 0.8 |
Eligibility Criteria
Inclusion Criteria
- Endometriosis diagnosed by laparoscopy
Exclusion Criteria
- Known allergy to resveratrol
- Use of gonadotropin or danazol in the last month
Data sourced from ClinicalTrials.gov (NCT02475564) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.